Caris Life Sciences Inc (CAI)

Currency in USD
20.95
+0.76(+3.76%)
Closed·
20.57-0.38(-1.81%)
·
CAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.2021.00
52 wk Range
16.2842.50
Key Statistics
Prev. Close
20.19
Open
20.38
Day's Range
20.2-21
52 wk Range
16.28-42.5
Volume
1.84M
Average Vol. (3m)
2.46M
1-Year Change
-
Book Value / Share
2.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.69
Upside
+41.73%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Caris Life Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Caris Life Sciences Inc Earnings Call Summary for Q4/2025

  • Q4 2025 revenue surged 125% YoY to $293M; EPS of $0.28 beat expectations; gross margin improved to 75% from 54% in Q4 2024.
  • Molecular profiling services revenue jumped 199% YoY, driving strong performance; adjusted EBITDA reached $106M with $39.7M free cash flow.
  • Stock rose 0.87% after-hours to $18.47, but remains down 50% over six months and 55% below 52-week high of $42.50.
  • Analysts maintain strong buy consensus with price targets of $26-$45; however, full-year profitability not expected despite Q4 results.
  • CEO expressed confidence in growth momentum through strategic investments; risks include market competition, regulatory changes, and economic fluctuations.
Last Updated: 02/26/2026, 05:47 PM
Read Full Transcript
Caris Life Sciences investor slides for Q4/2025
Caris Life Sciences Q4 2025 slides
Last Update: Feb 26, 2026
See full investor slides

Compare CAI to Peers and Sector

Metrics to compare
CAI
Peers
Sector
Relationship
P/E Ratio
−11.0x−4.6x−0.5x
PEG Ratio
−0.15−0.090.00
Price / Book
10.3x2.7x2.6x
Price / LTM Sales
7.3x10.0x3.2x
Upside (Analyst Target)
48.6%60.8%47.6%
Fair Value Upside
Unlock−12.6%6.1%Unlock

Analyst Ratings

11 Buy
2 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.69
(+41.73% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy31.00+47.97%35.00MaintainApr 13, 2026
Jefferies
Buy28.00+33.65%-New CoverageApr 13, 2026
Piper Sandler
Hold21.00+0.24%-New CoverageApr 10, 2026
Evercore ISI
Buy30.00+43.20%34.00MaintainApr 06, 2026
Goldman Sachs
Buy27.00+28.88%-New CoverageApr 01, 2026

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
0.28 / --
Revenue / Forecast
292.9M / --
EPS Revisions
Last 90 days

CAI Income Statement

People Also Watch

18.37
KVYO
+8.44%
207.19
NTRA
-3.47%
168.30
CRDO
+5.50%
824.01
LITE
-3.37%
1,030.81
FICO
+2.34%

FAQ

What Is the Caris Life Sciences (CAI) Stock Price Today?

The Caris Life Sciences stock price today is 20.95 USD.

What Stock Exchange Does Caris Life Sciences Trade On?

Caris Life Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Caris Life Sciences?

The stock symbol for Caris Life Sciences is "CAI."

What Is the Caris Life Sciences Market Cap?

As of today, Caris Life Sciences market cap is 5.71B USD.

What Is Caris Life Sciences's Earnings Per Share (TTM)?

The Caris Life Sciences EPS (TTM) is -3.22.

When Is the Next Caris Life Sciences Earnings Date?

Caris Life Sciences will release its next earnings report on Jun 03, 2026.

From a Technical Analysis Perspective, Is CAI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Caris Life Sciences Stock Split?

Caris Life Sciences has split 0 times.

How Many Employees Does Caris Life Sciences Have?

Caris Life Sciences has 1846 employees.

What is the current trading status of Caris Life Sciences (CAI)?

As of Apr 16, 2026, Caris Life Sciences (CAI) is trading at a price of 20.95 USD, with a previous close of 20.19 USD. The stock has fluctuated within a day range of 20.20 USD to 21.00 USD, while its 52-week range spans from 16.28 USD to 42.50 USD.

What Is Caris Life Sciences (CAI) Price Target According to Analysts?

The average 12-month price target for Caris Life Sciences is 29.69 USD, with a high estimate of 38 USD and a low estimate of 21 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +41.73% Upside potential.

What Is the CAI Premarket Price?

CAI's last pre-market stock price is 20.49 USD. The pre-market share volume is 28,540.00, and the stock has decreased by 0.30, or 1.49%.

What Is the CAI After Hours Price?

CAI's last after hours stock price is 20.57 USD, the stock has decreased by -0.38, or -1.81%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.